Cooperativity between Ras pathway mutations in colonic tumorigenesis
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
The Kirsten rat sarcoma ( KRAS ) gene is the most frequently mutated oncogene in colorectal cancer (CRC). We previously characterized two activating alleles of KRAS , A59T and A59E, that show impaired BRAF dimerization. These alleles of KRAS are enriched in CRC tumors with genetic alterations in genes that regulate MAPK signaling (e.g. EGFR, NF1). Using a new conditional mouse model of K-Ras (LSL-K-Ras A59E) we show that, despite its inability to universally activate RAF kinases, K-Ras A59E disturbs colon epithelium and decreases mouse survival in a tumor model. By combining LSL-K-Ras A59E mice with a conditional knockout of Nf1, we demonstrate cooperation between these alleles at multiple levels. Consistent with cooperation and clinical observations, we show that K-Ras A59E neither promotes EGF independence of organoid growth, nor confers intrinsic resistance to EGFR inhibition. Thus, our data provide a deeper understanding of the role of RAF isoforms in mutant KRAS driven CRC and argue for the use of anti-EGFR therapies against some Ala59 mutant alleles of KRAS.
Statement of significance
Our studies on oncogenic K-RAS mutants demonstrate that the biochemical properties of a mutant oncoprotein are reflected in the somatic genetics of cancer, in particular in the cooperating mutations that occur. These mutant-specific genetic interactions influence therapeutic responses. As such, KRAS mutation may not be a univariate predictor of response to EGFR inhibition.
